Fig. 3From: Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerHuman epidermal growth factor receptor 2 (HER2) extracellular domain (ECD)/intracellular domain (ICD) ratio. pCR pathologic complete responseBack to article page